Patents and Patent Applications

9 Months Ended

Sep. 30, 2012

Patents and Patent Applications [Abstract]

Patents and Patent Applications

NOTE 2 — Patents and Patent Applications

As of September 30, 2012, we had approximately $1,939,000 in capitalized patent and patent application costs reflected on its balance sheet. Of this amount, $1,594,000 relates to patent and patent application costs for Androxal® and $345,000 relates to patent and patent application costs for Proellex®.

Should we not continue development of either drug candidate or should we not continue as a going concern, the remaining capitalized patent and patent application costs may not be recoverable, which would result in charges to operating results in future periods.